Abivax Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	251.94	251.94	26.95	60.7
Short-Term Investments	9.19	9.19	0	0
Cash & Cash Equivalents	261.13	261.13	26.95	60.7
Cash Growth	-	868.94%	-55.60%	-
Other Current Assets	24.84	24.84	9.23	14.78
Total Current Assets	285.97	285.97	36.18	75.49
Property, Plant & Equipment	0.88	0.88	1.59	0.31
Long-Term Investments	12.87	12.87	11.71	1.34
Goodwill and Intangibles	25.02	25.02	25.03	32.1
Other Long-Term Assets	2.32	2.32	1.04	0
Total Long-Term Assets	41.09	41.09	39.36	33.75
Total Assets	327.06	327.06	75.54	109.23
Accounts Payable	47.22	47.22	15.48	18.56
Deferred Revenue	0.05	0.05	0.13	0.16
Current Debt	14.12	14.12	14.22	11.35
Other Current Liabilities	8.65	8.65	2.3	2.2
Total Current Liabilities	70.04	70.04	32.13	32.27
Long-Term Debt	60.35	60.35	35.01	40.31
Other Long-Term Liabilities	0.66	0.66	1.22	10.72
Total Long-Term Liabilities	61.01	61.01	36.22	51.03
Total Liabilities	131.05	131.05	68.36	83.3
Total Debt	74.47	74.47	49.23	51.65
Debt Growth	-	51.26%	-4.69%	-
Retained Earnings	-282.95	-282.95	-143.51	-81.81
Shareholders' Equity	196.01	196.01	7.19	25.93
Net Cash / Debt	186.66	186.66	-22.28	9.05
Net Cash Per Share	4.33	4.33	-1.17	0.59
Working Capital	215.93	215.93	4.05	43.22
Book Value Per Share	4.55	4.55	0.38	1.68

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).